XLO Stock Forecast: Xilio Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Xilio Therapeutics, Inc. is $19. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 68 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Xilio Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
XLO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on XLO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | Raymond James | Initiates | Outperform | $16 |
| 6 Aug 2025 | Leerink Partners | Initiates | Outperform | $2.00 |
| 8 Nov 2024 | Raymond James | Maintains | Outperform | — |
| 30 May 2023 | Chardan Capital | Reiterates | Buy | — |
| 11 May 2023 | Chardan Capital | Reiterates | Buy | — |
| 27 Jan 2023 | Morgan Stanley | Maintains | Overweight | — |
| 21 Dec 2022 | Chardan Capital | Initiates | Buy | — |
| 10 Nov 2022 | Raymond James | Maintains | Outperform | — |
| 10 Aug 2022 | Morgan Stanley | Maintains | Overweight | — |
| 10 Jan 2022 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Nov 2021 | Cowen & Co. | Initiates | Outperform | — |
| 16 Nov 2021 | Morgan Stanley | Initiates | Overweight | — |
| 16 Nov 2021 | Raymond James | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for XLO.
This page is one stock. Monday covers all of them.
XLO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
XLO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Xilio Therapeutics, Inc. returned −28.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
XLO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 11.6×
- Price / sales
- 1.0×
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 67% of US stocks
Cheaper than 67% of US stocks
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −74.9%
- Net margin
- —
Higher than 16% of US stocks
- Return on equity
- −38.2%
- Return on assets
- −19.2%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Xilio Therapeutics, Inc. has a market value of $53.4M.
Revenue in the twelve months to 30 June 2026: $64.1M. The latest quarter grew 131.2% year on year.
Net income over the same four quarters: −$21.8M, a −34.1% net margin.
Diluted earnings per share, trailing twelve months: −$1.64.
Free cash flow in the twelve months to 30 June 2026: −$61.3M.
Trailing P/E: 11.6×.
Xilio Therapeutics, Inc. employs 76 people — $843K of revenue per employee.
Data provided by Twelve Data
XLO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at XLO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Xilio Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about XLO
What is the XLO stock price forecast for 2026-2027?
The median 12-month analyst price target for Xilio Therapeutics, Inc. is $19, with estimates ranging from $16 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is XLO stock a buy right now?
Of the 2 analysts covering Xilio Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xilio Therapeutics, Inc. 68 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank XLO?
As at 21 Nov 2026, Xilio Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
Will XLO stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $19, and Ticker Nerd's factor model ranks Xilio Therapeutics, Inc. 68 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the XLO stock forecast for 2030?
No analyst covering Xilio Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XLO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $21 over the next 12 months.
How has XLO stock performed over the past year?
Xilio Therapeutics, Inc. returned -28.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Xilio Therapeutics, Inc. do?
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer. Its current portfolio centers on tumor-activated biologics designed to localize immune activity within the tumor microenvironment while aiming to reduce systemic side effects associated with broader immunotherapies.
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology therapies for cancer. Its current portfolio centers on tumor-activated biologics designed to localize immune activity within the tumor microenvironment while aiming to reduce systemic side effects associated with broader immunotherapies. The company’s pipeline includes investigational checkpoint inhibitors, cytokines, and immune-cell engaging therapies, with programs spanning solid tumors and other cancer settings. Xilio Therapeutics also uses its proprietary platform to engineer tumor-selective molecules such as antibodies and cytokine-based candidates, which are intended to support more precise immune responses. Based in Waltham, Massachusetts, Xilio Therapeutics plays a role in advancing next-generation oncology treatments across the biotechnology and pharmaceutical markets.
CEO Dr. Rene Russo BCPS, Pharm.D. · 76 employees · United States · https://xiliotx.com